HURA vs HYFT

TuHURA Biosciences, Inc. vs MindWalk Holdings Corp. — Valuation Comparison 2026

HURA

Pharmaceutical Preparations
TuHURA Biosciences, Inc.
Quality
2.9
out of 10
Value Trap
43
WARN
Price
$2.26
Last close
Models
7/13
Active
VS

HYFT

Pharmaceutical Preparations
MindWalk Holdings Corp.
Quality
1.7
out of 10
Value Trap
Price
$1.76
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType HURA Fair ValueHURA Upside HYFT Fair ValueHYFT Upside
Bayesian DCF Intrinsic $0.31 -86.4% $0.42 -75.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $1.06 -53.3% $0.12 -90.6%
PWERM Option-Based $2.30 +1.9% $1.40 -20.7%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for HURA vs HYFT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

HURA vs HYFT — Which Stock Is More Undervalued?

HURA scores higher with a 2.9/10 quality rating vs HYFT's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing TuHURA Biosciences, Inc. (HURA) and MindWalk Holdings Corp. (HYFT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

HURA currently trades at $2.26 with a QOC of 2.9/10, while HYFT trades at $1.76 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).